NICE Final Guidance Backs Fezolinetant When HRT Is Unsuitable

NICE has issued final guidance recommending fezolinetant, sold as Veoza, as an NHS option in England for moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsuitable.

The chronology matters. NICE announced final draft guidance on March 11, 2026. The final technology appraisal, TA1143, was published on March 31. Describing the earlier announcement as completed final approval collapses two distinct stages of the appraisal process.

The recommendation is also narrower than a general endorsement for everyone with menopause symptoms. Fezolinetant treats vasomotor symptoms, and its use requires assessment of suitability, potential interactions and liver risk. It does not replace individualized discussion of HRT or address every effect of menopause.

The March 11 Announcement Was Final Draft Guidance

NICE's March 11 announcement said an estimated 500,000 people in England could be eligible for fezolinetant. On that date, however, the recommendation was still final draft guidance. NICE's document history records publication of the final appraisal document and committee papers on March 11, followed by final guidance on March 31.

The final recommendation says fezolinetant can be used for moderate to severe vasomotor symptoms associated with menopause when HRT is unsuitable. Hot flushes and night sweats are vasomotor symptoms. The drug is taken as a 45 mg tablet once daily and works as a neurokinin-3 receptor antagonist, acting on signaling involved in temperature regulation rather than supplying estrogen.

NICE says NHS England commissioners must fund the treatment within 90 days of final publication when a clinician considers it the most suitable option under the guidance. That funding duty is not the same as an automatic prescription for every potentially eligible person. Clinical assessment and prescribing safeguards still apply.

The 500,000 figure is therefore an estimate of potential eligibility, not a forecast that 500,000 prescriptions will be issued. Actual use will depend on symptoms, whether HRT is suitable, medical history, liver-test results, patient preference and clinician judgment.

The Final Recommendation Is Narrower Than a General NHS Approval

NICE concluded that clinical trials showed fezolinetant reduced the frequency and severity of vasomotor symptoms compared with placebo. It also noted an important evidence limitation: there was no direct comparison with other nonhormonal treatments. Indirect comparisons suggested similar effectiveness, but NICE described those results as uncertain.

That distinction limits claims that fezolinetant is categorically superior to existing alternatives. The final appraisal supports it as a cost-effective option for a defined group, not as the best treatment for every patient or as a replacement for HRT where HRT remains appropriate.

Fezolinetant targets hot flushes and night sweats. It is not established in this guidance as a treatment for other menopause-related concerns such as vaginal symptoms or bone loss. A person may therefore need a broader care plan even if the drug reduces vasomotor symptoms.

Statements that all people with a history of cancer, blood clots or cardiovascular disease cannot use HRT are also too broad. Suitability depends on the type of HRT, the person's diagnosis, treatment history and individual risk. The NICE recommendation uses the more careful threshold that HRT is unsuitable, leaving that assessment to clinical care rather than a universal list.

Liver Monitoring Is Part of the Treatment

The Medicines and Healthcare products Regulatory Agency strengthened precautions for fezolinetant in 2025 after reports of serious drug-induced liver injury. The regulator says treatment should be avoided in people with known liver disease or those at higher risk of liver disease.

Liver-function tests are required before treatment begins. MHRA advises testing monthly during the first three months and periodically after that, with additional testing if symptoms suggest liver injury. Treatment should not start when specified liver enzymes or bilirubin are elevated, and it should be stopped when defined laboratory or clinical thresholds are reached.

Patients are advised to seek medical attention for possible warning signs including unusual fatigue, itching, yellowing of the skin or eyes, dark urine, pale stools, nausea, vomiting, reduced appetite or abdominal pain. These symptoms have many possible causes, but they require prompt assessment in someone taking fezolinetant.

The liver warning does not erase the potential benefit documented in the appraisal. It changes what responsible access looks like. A nonhormonal medicine is not automatically risk-free, and a once-daily tablet still carries a testing schedule that patients and services must be able to follow.

Access Must Include the Safety Burden

The final NICE decision expands a real treatment choice for people whose hot flushes or night sweats are moderate to severe and for whom HRT is unsuitable. That matters because vasomotor symptoms can disrupt sleep, daily activity and quality of life. But access should be described in the terms NICE actually set.

The March 11 final draft was an important milestone, not the final publication. The March 31 guidance created the operative recommendation. The estimated eligible population describes scale, not guaranteed uptake. Trial evidence showed benefit against placebo, while comparison with other nonhormonal options remained uncertain.

The harder implementation question is whether routine care can deliver both the medicine and its monitoring. Prescribers need to document why HRT is unsuitable, check liver status and interactions, arrange repeat blood tests and respond quickly to abnormal results or symptoms. Patients need a clear explanation of what the drug can treat and what it cannot.

Fezolinetant broadens menopause care without resolving it. The strongest version of the NHS story is not that a risk-free replacement for hormones has arrived. It is that a defined group now has another evidence-assessed option, paired with a safety obligation that should be visible every time the benefit is discussed.